Risk factor
Very poor trading liquidity
Profitability factor
Weak growth
About
Operating as a key healthcare provider in Indonesia, PT Bundamedik Tbk (also known as PT Bunda Medik) had a significant footprint as of December 31, 2021. Its facilities included two maternal and child hospitals, three general hospitals, two clinics, ten specialized in-vitro fertilization (IVF) centers, and fourteen diagnostic laboratories. Beyond its direct medical services, the company diversified into the distribution of pharmaceuticals and medical equipment, alongside interests in the hotel industry, medical tourism, and management consulting. Established in 1973, PT Bundamedik Tbk is headquartered in Jakarta Pusat, Indonesia, and operates as a subsidiary of PT Bunda Investama Indonesia.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD
Target Price
The average target price of BMHS.JK is 220 and suggests 14.6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat